Literature DB >> 11074879

An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation.

C C Wu1, S R Hsieh, J T Chen, W L Ho, M C Lin, D C Yeh, T J Liu, F K P'eng.   

Abstract

BACKGROUND: The role of surgical resection for hepatocellular carcinoma with tumor thrombi involving the major portal vein is controversial because of a high operative risk and poor prognosis. Previously, a resection was performed only when the tumor thrombi were limited to the first branch of the portal vein without extension to the portal bifurcation. HYPOTHESIS: Concomitant liver and portal vein resection may be beneficial in patients with hepatocellular carcinoma with tumor thrombi extending to portal bifurcation.
DESIGN: Retrospective review.
SETTING: University hospital, tertiary referral center. PATIENTS: Among 368 patients with hepatocellular carcinoma who underwent a curative resection, portal vein involvement occurred in 112 patients. Fifteen of the 112 patients underwent a concomitant liver and portal vein resection owing to extension of tumor thrombi to the portal bifurcation (group 1). The remaining 97 patients did not need portal vein resection (group 2). INTERVENTION: Surgical indications, procedures, and results of pathological examination of resected specimens were assessed in patients in group 1. The clinicopathological characteristics, operative morbidity and mortality, and operative results were compared between the 2 groups. MAIN OUTCOME MEASURES: Disease-free and actuarial survival rates.
RESULTS: Intramural tumor infiltration was found at the site of thrombi adhesion to the portal vein cuff in 11 of 15 patients in group 1. Owing to patient selection bias, patients in group 1 were significantly younger and had better liver function and greater resected liver weight. The operative time, postoperative hospitalization, operative blood loss, amount of blood transfusion, and operative morbidity and mortality did not differ significantly between the 2 groups. The 5-year disease-free survival rates of groups 1 and 2 were 21.6% and 20.4% (P =.19), respectively, while the actuarial survival rates were 26. 4% and 28.5% (P =.33), respectively.
CONCLUSION: Liver resection with partial resection of the portal vein is justified in selected patients with hepatocellular carcinoma with tumor thrombi extending to portal bifurcation.

Entities:  

Mesh:

Year:  2000        PMID: 11074879     DOI: 10.1001/archsurg.135.11.1273

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  33 in total

Review 1.  Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus.

Authors:  Masami Minagawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

2.  Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.

Authors:  Hidetoshi Nitta; Toru Beppu; Katsunori Imai; Hiromitsu Hayashi; Akira Chikamoto; Hideo Baba
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

Review 3.  Evolving role of vascular resection and reconstruction in hepatic surgery for malignancy.

Authors:  Kristin L Mekeel; Alan W Hemming
Journal:  Hepat Oncol       Date:  2013-12-20

4.  Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy.

Authors:  Nan Li; Shuang Feng; Jie Xue; Xu-Biao Wei; Jie Shi; Wei-Xing Guo; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng; Yan Meng
Journal:  HPB (Oxford)       Date:  2016-05-07       Impact factor: 3.647

Review 5.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Authors:  Stephen L Chan; Charing C N Chong; Anthony W H Chan; Darren M C Poon; Kenneth S H Chok
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 6.  Update in management of hepatocellular carcinoma in Eastern population.

Authors:  Kevin Ka Wan Chu; Tan To Cheung
Journal:  World J Hepatol       Date:  2015-06-18

Review 7.  Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.

Authors:  Su Jong Yu; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2015-06-18

Review 8.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

9.  Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study.

Authors:  Qing-he Tang; Ai-jun Li; Guang-ming Yang; Eric C H Lai; Wei-ping Zhou; Zhi-hao Jiang; Wan Yee Lau; Meng-chao Wu
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

Review 10.  Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Simone Conci; Alessandro Valdegamberi; Marco Vitali; Francesca Bertuzzo; Michela De Angelis; Guido Mantovani; Calogero Iacono
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.